Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone

Bibliography

• Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E: Effects of prescription omega‑3‑acid ethyl esters on non‑high‑density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin. Proc. 85(2), 122–128 (2010)
   Google Scholar
• Benn M, Nordestgaard BG, Jensen GB, Tybjaerg‑Hansen A: Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 661–670 (2007).
   Google Scholar
• Robinson JG, Wang S, Smith BJ, Jacobson TA: Meta‑analysis of the relationship between non‑high‑density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53, 316–322 (2009).
   Google Scholar
• ▪▪ Clearly demonstrates that non-HDL-C is a good predictor of cardiovascular disease risk.
   Google Scholar
• Graham I, Atar D, Borch‑Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prev. Rehabil. 14, S1–S113 (2007).
   Google Scholar
• Reiner Ž: Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. 24, 19–28 (2010).
   Google Scholar
• ▪ Review of combination therapy of dyslipidemia, including omega-3 fatty acids plus statins.
   Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Diab. Vasc. Dis. Res. 5, 319–355 (2008).
   Google Scholar
• Reiner Ž, Tedeschi‑Reiner E, Štajminger G: The role of omega‑3 fatty acids from fish in prevention of cardiovascular diseases. Lijec. Vjesn. 129, 350–355 (2007).
   Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102, K1–K34 (2008).
   Google Scholar
• ▪ Important review of atherogenic dyslipidemia and the present possibilities of treatment.
   Google Scholar
• Reiner Ž, Salzer B: The effects of omega‑3 fatty acids on serum lipoproteins and apoproteins in patients with hyperlipoproteinaemia. Period. Biol. 95, 484 (1993).
   Google Scholar
• Salzer B, Reiner Ž, Stavljenić A: A hypolipemic effect of omega‑3‑ fatty acids in type V hyperlipoproteinemia. Presented at: IX European Congress of Clinical Chemistry. Krakow, Poland, 8–14 September 1991 (Abstract 131).
   Google Scholar
• Durrington PN, Bhatnagar D, Mackness MI et al.: An omega‑3‑polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85, 544–548 (2001).
   Google Scholar
• Davidson MH, Stein EA, Bays HE et al.; Combination of prescription Omega‑3 with Simvastatin (COMBOS) Investigators: Efficacy and tolerability of adding prescription omega‑3 fatty acids 4 g/day to simvastatin 40 mg/day in hypertriglyceridemic patients: an 8‑week, randomized, double‑blind, placebo‑controlled study. Clin. Ther. 29, 1354–1367 (2007).
   Google Scholar
• Chan DC, Watts GF, Nguyen MN, Barrett PH: Factorial study of the effect of n‑3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A‑I and A‑II in men with abdominal obesity. Am. J. Clin. Nutr. 84, 37–43 (2006).
   Google Scholar
• Nakamura N, Hamazaki T, Ohta M et al.: Joint effects of HMG‑CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int. J. Clin. Lab. Res. 29, 22–25 (1999).
   Google Scholar
• Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR: Effects of adding prescription omega‑3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 102, 429–433 (2008).
   Google Scholar
• Zeman M, Zák A, Vecka M, Tvrzická E, Písaríková A, Stanková B: N‑3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin‑fibrate combination. J. Nutr. Biochem. 17, 379–384 (2006).
   Google Scholar
• Preis SR, Hwang S‑J, Coady S et al.: Trends in all‑cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham heart study, 1950 to 2005. Circulation 7, 1728–1735 (2009).
   Google Scholar
• Merkler M, Reiner Ž: The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundament. Clin. Pharmacol. 21(Suppl. 2), 1–3 (2007).
   Google Scholar
• Reiner Ž: How to improve cardiovascular diseases prevention in Europe? Nutr. Metab. Cardiovasc. Dis. 19, 451–454 (2009).
   Google Scholar
• GISSI‑Prevenzione Investigators: Dietary supplementation with n‑3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‑Prevenzione trial. Lancet 354, 447–455 (1999).
   Google Scholar
• ▪▪ Important trial demonstrating that prescription omega-3 fatty acid ethyl esters can reduce all-cause mortality in postmyocardial patients.
   Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M et al.; Japan EPA Lipid Intervention Study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open‑label, blinded end point analysis. Lancet 369, 1090–1098 (2007).
   Google Scholar
• Saito Y, Yokoyama M, Origasa H et al.; JELIS Investigators: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‑analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200, 135–140 (2008)
   Google Scholar